Environmental contamination, a legacy of industrial activity borne by numerous sites around the world, poses health risks for surrounding communities and presents serious cleanup challenges. One such site, the Santa Susana Field Laboratory (SSFL), served as an aerospace and nuclear energy research facility for over 50 years, during which time radioactive and other hazardous materials were unintentionally and intentionally released into the surrounding environment. These releases, including the partial meltdown of a sodium reactor, were hidden from the public for three decades. The site is now located in suburban Los Angeles, with 730,000 people living within a 10-mile radius. This paper evaluates the technical and social challenges underlying site cleanup at SSFL, including a complex geological setting, uncertain contaminant information, and a convoluted, evolving regulatory framework. These challenges, paired with historical secrecy on the part of responsible organizations and unclear layers of responsibility, have led to uncertainty and distrust within the surrounding community. Lessons learned from other remediated sites are assessed and recommendations for the SSFL cleanup are provided.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/s00267-019-01239-7 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Seven-year analysis of adjuvant pembrolizumab versus placebo in stage III melanoma in the EORTC1325 / KEYNOTE-054 trial.
Eur J Cancer
November 2024
Gustave Roussy Cancer Campus Grand Paris & University Paris-Saclay, Villejuif, France.
Article Synopsis
- A phase 3 trial found that 12 months of adjuvant pembrolizumab significantly improved recurrence-free survival (RFS) and distant metastasis-free survival (DMFS) in patients with high-risk stage III melanoma compared to placebo, with longer follow-up data available.
- With a median follow-up of 6.9 years, the pembrolizumab group showed a 50% RFS at 7 years versus 36% for the placebo group, and a 54% DMFS compared to 42% in the placebo group.
- The results indicated consistent positive outcomes across various melanoma subtypes, confirming the long-term benefits of pembrolizumab in improving survival metrics in these patients.
Efficacy and Safety of Ceftazidime-Avibactam Alone versus Ceftazidime-Avibactam Plus Fosfomycin for the Treatment of Hospital-Acquired Pneumonia and Ventilator-Associated Pneumonia: A Multicentric Retrospective Study from the SUSANA Cohort.
Antibiotics (Basel)
July 2024
Unit of Infectious Diseases, Department of Medicine, Surgery and Pharmacy, University of Sassari, 07100 Sassari, Italy.
Hospital-acquired pneumonia (HAP) and ventilation-associated pneumonia (VAP) are challenging clinical conditions due to the challenging tissue penetrability of the lung. This study aims to evaluate the potential role of fosfomycin (FOS) associated with ceftazidime/avibactam (CZA) in improving the outcome in this setting. We performed a retrospective study including people with HAP or VAP treated with CZA or CZA+FOS for at least 72 h.
View Article and Find Full Text PDFHow shared suffering bonded Britons witnessing the Queen's funeral.
Sci Rep
July 2024
School of Anthropology & Museum Ethnography, Oxford University, Oxford, UK.
Previous research suggests that sharing emotionally intense experiences with others, for example by undergoing dysphoric collective rituals together, can lead to "identity fusion," a visceral feeling of oneness that predicts group cohesion and self-sacrifice for the group. In this pre-registered research, we provide the first quantitative investigation of identity fusion following participation in a national funeral, surveying 1632 members of the British public. As predicted, individuals reporting intense sadness during Queen Elizabeth II's funeral exhibited higher levels of identity fusion and pro-group commitment, as evidenced by generosity pledges to a British Monarchist charity.
View Article and Find Full Text PDFReal-World Effectiveness and Safety of Cladribine in Multiple Sclerosis: Longitudinal Data From the Nationwide Registry in Argentina.
Clin Neuropharmacol
July 2024
Neuroimmunology Unit, Department of Neuroscience, Hospital Aleman, Buenos Aires, Argentina.
Article Synopsis
- The study evaluated the effectiveness and safety of cladribine (CLAD) for treating relapsing-remitting multiple sclerosis in 240 patients across Argentina, focusing on clinical relapses and disease progression over 24 months.
- Results showed a significant decrease in annual relapse rates from 1.19 to 0.19, with many patients achieving no evidence of disease activity (NEDA) at both 12 months (84.2%) and 24 months (77%).
- The study also monitored lymphopenia, finding that grade 1 lymphopenia was the most common, while severe grade 4 lymphopenia was rare, suggesting CLAD is a safe treatment option.
Spanish Society of Medical Oncology recommendations for comprehensive assessment and care of cancer survivors' needs.
Clin Transl Oncol
January 2025
Department of Oncology, University Hospital of Navarra, Instituto de Investigación Sanitaria de Navarra, IdISNA, Pamplona, Spain.
This article reviews the contemporary and inclusive definition of cancer survivorship, including patients with and without disease who have completed or continue to undergo treatment. The Spanish Society of Medical Oncology (SEOM) describes in this article the needs of these patients and outlines a care model based on an estimation of cancer incidence and identification of patient needs, to enable the provision of practical actions to achieve effective care. The objectives of this review are to identify the main effects of cancer on survivors and to establish appropriate ways of measuring these effects, as well as discussing the management of physical, psychological and social, occupational, financial, and other health-related needs.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!